BioSpace News Archive

Business

MD Anderson Cancer Center and 4D pharma collaborate to evaluate live biotherapeutics in solid tumors

The University of Texas MD Anderson Cancer Center and 4D pharma today announced a strategic collaboration to evaluate 4D’s live biotherapeutic oncology pipeline across a range of cancer settings.

January 8, 2019
·
3 min read
EVOTEC INVESTS IN FINANCING ROUND OF EXSCIENTIA

$ 26 M FINANCING ROUND (SERIES B) INCLUDES CELGENE, GT HEALTHCARE CAPITAL PARTNERS AND EVOTEC

January 8, 2019
·
5 min read
Business

AYOXXA signs research agreement in the field of ophthalmology with one of the leading pharmaceutical companies

Agreement targets the development of low volume and high sensitivity multiplex assays for aqueous humor protein profiling for biomarker identification and validation in support of drug discovery in ophthalmology

January 8, 2019
·
4 min read
Business

MD Anderson Cancer Center and Nanobiotix announce a large-scale, comprehensive clinical collaboration on NBTXR3

Collaboration will initially support nine new phase I/II clinical trials with Nanobiotix’s first-in-class agent NBTXR3 for use in treating six cancer types

January 8, 2019
·
3 min read
Pharm Country

Dose Escalation in Liver Cancer Study with ADP-A2AFP (AFP) SPEAR T-cells and Moving to Expansion Phase in ADP-A2M10 (MAGE-A10) Lung Cancer Study after Favorable Safety Reviews

Adaptimmune Therapeutics plc today announced that the Safety Review Committee (SRC) has endorsed dose escalation in the ongoing ADP-A2AFP (AFP) study in patients with hepatocellular carcinoma (liver cancer) to the second dose cohort.

January 8, 2019
·
5 min read
Deals

It’s a Wrap! Takeda-Shire Merger Is a Done Deal, Making Takeda the Largest Mass. Biotech Employer

Last year’s sole mega-deal, the acquisition of Dublin-based Shire by Japan-based Takeda Pharmaceutical is finally closed. Takeda, 237 years old, is now a top 10 international drug company.

January 8, 2019
·
3 min read
·
Mark Terry
Drug Development

Novartis Talks Move to Cell and Gene Therapies at JPM

In an interview with CNBC Monday, Novartis Chief Executive Officer Vas Narasimhan noted that the company is looking to become an entity that doesn’t draw its profits from treating disease, but will make money by providing cures.

January 8, 2019
·
3 min read
·
Alex Keown
Business

Seven Former FDA Commissioners Offer Reasons for Agency Independence

In theory, the U.S. Food and Drug Administration (FDA) is tasked with overseeing the safety of food and drugs in the U.S. based on science, not politics. That doesn’t always work.

January 8, 2019
·
3 min read
·
Mark Terry
Business

Amgen Execs Speak on Majority of Repatha Medicare Patients Now Having Low-Cost Access

Amgen continues to move toward completing its promise of shifting patients to a cheaper cost of its blockbuster anti-cholesterol drug Repatha, a PCSK9 (proprotein convertase subtilisin kexin type 9) inhibitor.

January 8, 2019
·
2 min read
·
Alex Keown
Drug Development

After Announcing a New CEO, UroGen Touts Positive Phase III Data for Urothelial Cancer

UroGen Pharma, based in New York, announced positive topline results from its Phase III OLYMPUS clinical trial. The trial evaluated UGN-101 (mitomycin gel) for instillation for the non-surgical treatment of low-grade upper tract urothelial cancer (UTUC).

January 8, 2019
·
2 min read
·
Mark Terry